Can a diabetes drug tame blood sugar swings after bariatric surgery?

NCT ID NCT07515391

ENROLLING_BY_INVITATION Disease control Sponsor: Dasman Diabetes Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether dapagliflozin, a diabetes drug, can reduce dangerous blood sugar highs and lows in people who have had bariatric surgery. The study will enroll 30 participants, both with and without type 2 diabetes, and monitor glucose levels continuously for 12 weeks. The goal is to see if the drug improves overall glucose control and reduces hypoglycemia and hyperglycemia episodes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin (a diabetes drug that helps the kidneys remove extra sugar through urine)
What this could lead to: If it works, this could show that dapagliflozin helps stabilize blood sugar levels after bariatric surgery, potentially improving diabetes management.
What could go wrong: This is a small, early-phase study with only 30 participants, so results may not apply to everyone. The drug also carries risks like dehydration or urinary infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARIATRIC SURGERY CANDIDATE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BARIATRIC SURGERY CANDIDATE TYPE2 DIABETES

Contacts and locations

Locations

Dasman Diabetes Institute

Kuwait City, Dasman, 15462, Kuwait

More trials for these conditions

Other studies related to the condition(s) this trial covers.